MCID: LNG032
MIFTS: 94

Lung Cancer

Categories: Genetic diseases, Cancer diseases, Respiratory diseases

Aliases & Classifications for Lung Cancer

MalaCards integrated aliases for Lung Cancer:

Name: Lung Cancer 54 12 24 25 71 29 41 3 14
Non-Small Cell Lung Carcinoma 38 12 14 69
Lung Carcinoma 12 24 52 14
Adenocarcinoma of Lung, Response to Tyrosine Kinase Inhibitor in 54 13
Nonsmall Cell Lung Cancer, Somatic 54 13
Lung Cancer, Protection Against 54 29
Adenocarcinoma of Lung, Somatic 54 24
Non-Small Cell Lung Cancer 12 29
Malignant Neoplasm of Lung 25 69
Nonsmall Cell Lung Cancer 54 71
Alveolar Cell Carcinoma 71 29
Lung Cancer, Somatic 54 24
Carcinoma of Lung 12 69
Lung Neoplasms 25 69
Nsclc 12 52
Nonsmall Cell Lung Cancer, Response to Tyrosine Kinase Inhibitor in 54
Primary Malignant Neoplasm of Lung 69
Bronchioloalveolar Adenocarcinoma 69
Carcinoma, Non-Small-Cell Lung 42
Carcinoma Non-Small Cell Lung 52
Malignant Tumor of Lung 25
Adenocarcinoma of Lung 71
Lung Malignant Tumors 25
Respiratory Carcinoma 25
Malignant Lung Tumor 25
Neoplasm of the Lung 29
Pulmonary Carcinoma 25
Pulmonary Neoplasms 25
Cancer of Bronchus 25
Cancer of the Lung 25
Lung Malignancies 25
Pulmonary Cancer 25
Neoplasm of Lung 29
Cancer of Lung 12
Lung Neoplasm 12
Cancer Lung 52
Lncr 71

Characteristics:

OMIM:

54
Inheritance:
autosomal recessive


HPO:

32
lung cancer:
Inheritance autosomal recessive inheritance


Classifications:



Summaries for Lung Cancer

MedlinePlus : 41 lung cancer is one of the most common cancers in the world. it is a leading cause of cancer death in men and women in the united states. cigarette smoking causes most lung cancers. the more cigarettes you smoke per day and the earlier you started smoking, the greater your risk of lung cancer. high levels of pollution, radiation and asbestos exposure may also increase risk. common symptoms of lung cancer include a cough that doesn't go away and gets worse over time constant chest pain coughing up blood shortness of breath, wheezing, or hoarseness repeated problems with pneumonia or bronchitis swelling of the neck and face loss of appetite or weight loss fatigue doctors diagnose lung cancer using a physical exam, imaging, and lab tests. treatment depends on the type, stage, and how advanced it is. treatments include surgery, chemotherapy, radiation therapy, and targeted therapy. targeted therapy uses substances that attack cancer cells without harming normal cells. nih: national cancer institute

MalaCards based summary : Lung Cancer, also known as non-small cell lung carcinoma, is related to asbestosis and colorectal cancer, and has symptoms including alveolar cell carcinoma, coughing and dyspnea. An important gene associated with Lung Cancer is BRAF (B-Raf Proto-Oncogene, Serine/Threonine Kinase), and among its related pathways/superpathways are Non-small cell lung cancer and Innate Immune System. The drugs Abraxane and Alimta have been mentioned in the context of this disorder. Affiliated tissues include lung, brain and breast, and related phenotypes are Decreased viability and cellular

UniProtKB/Swiss-Prot : 71 Lung cancer: A common malignancy affecting tissues of the lung. The most common form of lung cancer is non-small cell lung cancer (NSCLC) that can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. NSCLC is often diagnosed at an advanced stage and has a poor prognosis.

CDC : 3 Lung cancer is the leading cause of cancer death and the second most common cancer among both men and women in the United States.

Genetics Home Reference : 25 Lung cancer is a disease in which certain cells in the lungs become abnormal and multiply uncontrollably to form a tumor. Lung cancer may or may not cause signs or symptoms in its early stages. Some people with lung cancer have chest pain, frequent coughing, breathing problems, trouble swallowing or speaking, blood in the mucus, loss of appetite and weight loss, fatigue, or swelling in the face or neck. Lung cancer occurs most often in adults in their sixties or seventies. Most people who develop lung cancer have a history of long-term tobacco smoking; however, the condition can occur in people who have never smoked.

OMIM : 54
Lung cancer is the leading cause of cancer deaths in the U.S. and worldwide. The 2 major forms of lung cancer are nonsmall cell lung cancer and small cell lung cancer (see 182280), which account for 85% and 15% of all lung cancers, respectively. Nonsmall cell lung cancer can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. Cigarette smoking causes all types of lung cancer, but it is most strongly linked with small cell lung cancer and squamous cell carcinoma. Adenocarcinoma is the most common type in patients who have never smoked. Nonsmall cell lung cancer is often diagnosed at an advanced stage and has a poor prognosis (summary by Herbst et al., 2008). (211980)

Disease Ontology : 12 A respiratory system cancer that is located in the lung.

Wikipedia : 72 Lung cancer, also known as lung carcinoma, is a malignant lung tumor characterized by uncontrolled cell... more...

Related Diseases for Lung Cancer

Diseases in the Lung Cancer family:

Lung Benign Neoplasm Lung Carcinoma in Situ
Lung Cancer, Egfr-Related Lung Cancer, Gstm1-Related

Diseases related to Lung Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 547)
id Related Disease Score Top Affiliating Genes
1 asbestosis 33.7 CASP8 FASLG GSTM1
2 colorectal cancer 33.1 BRAF CASP8 EGFR ERBB2 FASLG GSTM1
3 spinal cancer 32.7 ERBB2 FASLG
4 prostate cancer 32.3 CASP8 EGFR ERBB2 GSTM1 KRAS PIK3CA
5 pancreatic cancer 31.9 EGFR GSTM1 PIK3CA RASSF1 TP53
6 gallbladder cancer 31.9 EGFR ERBB2 KRAS PIK3CA PTEN TP53
7 myxedema 31.8 EGFR PIK3CA PTEN TP53
8 lymphopenia 31.8 EGFR PTEN TP53
9 measles 31.8 CASP8 EGFR ERBB2 GSTM1
10 nasopharyngeal carcinoma 31.4 EGFR PTEN TP53
11 hepatocellular carcinoma 31.3 CASP8 FASLG PIK3CA PTEN RASSF1 TP53
12 lung cancer susceptibility 3 12.1
13 gastric fundus cancer 12.0 CASP8 EGFR ERBB2 FASLG GSTM1 IRF1
14 lethal congenital contracture syndrome 10 12.0 BRAF EGFR ERBB2 KRAS PIK3CA PTEN
15 nail disorder, nonsyndromic congenital, 3, 11.9 EGFR ERBB2 FASLG GSTM1 KRAS PIK3CA
16 esophagus lymphoma 11.9 EGFR ERBB2 GSTM1 KRAS PIK3CA RASSF1
17 systemic lupus erythematosus with nephritis 2 11.9 CASP8 EGFR ERBB2 KRAS PIK3CA PTEN
18 trachea squamous cell carcinoma 11.9 EGFR ERBB2 KRAS PIK3CA PTEN TP53
19 zimmermann-laband syndrome 2 11.9 EGFR ERBB2 GSTM1 PIK3CA PTEN TP53
20 cervical cancer, somatic 11.8 EGFR ERBB2 GSTM1 KRAS RASSF1 TP53
21 adenosquamous cell lung carcinoma 11.8
22 gastric cancer, somatic 11.8 EGFR ERBB2 IRF1 KRAS PIK3CA TP53
23 lung cancer susceptibility 5 11.8
24 lung cancer susceptibility 4 11.8
25 lung cancer susceptibility 2 11.8
26 lung cancer, egfr-related 11.8
27 lung cancer, gstm1-related 11.8
28 endometriosis of uterus 11.8 EGFR ERBB2 KRAS PTEN TP53
29 rectum kaposi's sarcoma 11.8 EGFR ERBB2 PIK3CA PTEN TP53
30 brown-vialetto-van laere syndrome 11.8 EGFR ERBB2 KRAS PTEN TP53
31 hilar lung neoplasm 11.8
32 bernard-soulier syndrome, type c 11.8 BRAF EGFR KRAS PIK3CA PTEN RASSF1
33 asbestos-related lung carcinoma 11.8
34 lung carcinoma in situ 11.8
35 septicemic plague 11.8 CASP8 EGFR ERBB2 SLC22A18 TP53
36 glomus tympanicum tumor 11.8 EGFR ERBB2 PIK3CA PTEN TP53
37 small cell lung cancer, childhood 11.7
38 small cell lung cancer, adult 11.7
39 non-small cell lung cancer, childhood 11.7
40 sertoli-leydig cell tumor 11.7 BRAF EGFR ERBB2 KRAS TP53
41 peritoneal mesothelioma 11.7 BRAF KRAS PIK3CA PTEN TP53
42 ovarian brenner tumor 11.7 EGFR PIK3CA PTEN RASSF1 TP53
43 basaloid lung carcinoma 11.7
44 sohval soffer syndrome 11.7 BRAF EGFR ERBB2 KRAS
45 brenner tumor of the vagina 11.7 ERBB2 PIK3CA PTEN TP53
46 brenner tumor of ovary 11.7 ERBB2 PIK3CA PTEN TP53
47 occupational dermatitis 11.7 EGFR ERBB2 KRAS PIK3CA
48 juvenile astrocytoma 11.7 BRAF EGFR PTEN TP53
49 split-hand/foot malformation 4 11.7 KRAS PIK3CA PTEN TP53
50 dental caries 11.7 ERBB2 KRAS PIK3CA TP53

Graphical network of the top 20 diseases related to Lung Cancer:



Diseases related to Lung Cancer

Symptoms & Phenotypes for Lung Cancer

Symptoms via clinical synopsis from OMIM:

54

Lung:
alveolar cell carcinoma
non-small-cell cancer


Clinical features from OMIM:

211980

Human phenotypes related to Lung Cancer:

32
id Description HPO Frequency HPO Source Accession
1 alveolar cell carcinoma 32 HP:0006519

UMLS symptoms related to Lung Cancer:


coughing, dyspnea, fever, hemoptysis, snoring

GenomeRNAi Phenotypes related to Lung Cancer according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.62 PIK3CA KRAS BRAF EGFR
2 Decreased viability GR00106-A-0 10.62 KRAS
3 Decreased viability GR00221-A-1 10.62 PIK3CA DDR2 EGFR KRAS
4 Decreased viability GR00221-A-2 10.62 PIK3CA KRAS DDR2 MAP3K8
5 Decreased viability GR00221-A-3 10.62 ERBB2 MAP3K8
6 Decreased viability GR00221-A-4 10.62 PIK3CA BRAF DDR2 EGFR ERBB2 MAP3K8
7 Decreased viability GR00301-A 10.62 KRAS BRAF MAP3K8
8 Decreased viability GR00342-S-1 10.62 MAP3K8
9 Decreased viability GR00342-S-2 10.62 MAP3K8
10 Decreased viability GR00342-S-3 10.62 MAP3K8
11 Decreased viability GR00381-A-1 10.62 BRAF KRAS
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-134 10.41 ERCC6
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-148 10.41 ERCC6
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-150 10.41 MXRA5
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-160 10.41 MXRA5
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-167 10.41 CYP2A6
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-17 10.41 CASP8
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-187 10.41 MXRA5
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-20 10.41 ERCC6
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-200 10.41 ERCC6
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-209 10.41 ERCC6
22 Decreased shRNA abundance (Z-score < -2) GR00366-A-26 10.41 ERCC6
23 Decreased shRNA abundance (Z-score < -2) GR00366-A-28 10.41 CYP2A6
24 Decreased shRNA abundance (Z-score < -2) GR00366-A-55 10.41 MXRA5
25 Decreased shRNA abundance (Z-score < -2) GR00366-A-58 10.41 EGFR
26 Decreased shRNA abundance (Z-score < -2) GR00366-A-60 10.41 CASP8
27 Decreased shRNA abundance (Z-score < -2) GR00366-A-75 10.41 MXRA5
28 Decreased shRNA abundance (Z-score < -2) GR00366-A-77 10.41 ERCC6
29 Decreased shRNA abundance (Z-score < -2) GR00366-A-91 10.41 EGFR ERCC6 MXRA5 CASP8 CYP2A6
30 Decreased viability in esophageal squamous lineage GR00235-A 10 BRAF DDR2 ERBB2 ERCC6 FASLG KRAS
31 Decreased cell migration GR00055-A-1 9.85 BRAF DDR2 EGFR KRAS PIK3CA
32 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.8 EGFR ERBB2 GSTM1 MAP3K8 PTEN
33 Increased cell death HMECs cells GR00103-A-0 9.63 EGFR IRF1 MAP3K8 PIK3CA PTEN TP53
34 Decreased cella89culturea89derived Hepatitis C virus (HCVcc GR00234-A-2 9.61 BRAF DDR2 EGFR
35 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.44 CASP8 PRKN PTEN SLC22A18 TP53
36 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.44 BRAF CASP8 ERCC6 FASLG PRKN PTEN
37 Increased cell migration GR00055-A-3 9.35 BRAF DDR2 EGFR KRAS PIK3CA

MGI Mouse Phenotypes related to Lung Cancer:

44 (show all 23)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.47 MAP3K8 PIK3CA PRKN PTEN RASSF1 TP53
2 cardiovascular system MP:0005385 10.45 BRAF CASP8 DDR2 EGFR ERBB2 FASLG
3 homeostasis/metabolism MP:0005376 10.43 BRAF CASP8 DDR2 EGFR ERBB2 ERCC6
4 mortality/aging MP:0010768 10.37 FASLG IRF1 KRAS MAP3K8 PIK3CA PRKN
5 endocrine/exocrine gland MP:0005379 10.36 ERBB2 FASLG IRF1 KRAS PIK3CA PTEN
6 immune system MP:0005387 10.36 BRAF CASP8 EGFR ERCC6 FASLG IRF1
7 growth/size/body region MP:0005378 10.35 BRAF CASP8 DDR2 EGFR ERBB2 ERCC6
8 integument MP:0010771 10.35 IRF1 KRAS PIK3CA PRKN PTEN TP53
9 hematopoietic system MP:0005397 10.31 BRAF CASP8 EGFR ERCC6 FASLG IRF1
10 neoplasm MP:0002006 10.3 BRAF CASP8 DDR2 EGFR ERBB2 ERCC6
11 digestive/alimentary MP:0005381 10.24 BRAF EGFR ERBB2 FASLG KRAS MAP3K8
12 muscle MP:0005369 10.22 BRAF CASP8 DDR2 EGFR ERBB2 ERCC6
13 nervous system MP:0003631 10.21 FASLG KRAS PIK3CA PRKN PTEN TP53
14 adipose tissue MP:0005375 10.16 BRAF DDR2 EGFR ERCC6 PIK3CA PTEN
15 liver/biliary system MP:0005370 10.16 BRAF CASP8 EGFR ERCC6 FASLG KRAS
16 limbs/digits/tail MP:0005371 10.07 DDR2 EGFR ERBB2 ERCC6 KRAS PTEN
17 normal MP:0002873 10.06 BRAF EGFR ERBB2 FASLG IRF1 KRAS
18 renal/urinary system MP:0005367 9.92 KRAS PTEN TP53 BRAF CASP8 EGFR
19 reproductive system MP:0005389 9.91 BRAF DDR2 EGFR ERBB2 FASLG KRAS
20 respiratory system MP:0005388 9.81 BRAF CASP8 EGFR ERBB2 FASLG KRAS
21 pigmentation MP:0001186 9.77 BRAF EGFR KRAS PTEN TP53
22 skeleton MP:0005390 9.73 BRAF DDR2 EGFR ERBB2 ERCC6 FASLG
23 vision/eye MP:0005391 9.28 BRAF DDR2 EGFR ERCC6 FASLG KRAS

Drugs & Therapeutics for Lung Cancer

FDA approved drugs:

(show all 23)
id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Abraxane 17 46 PACLITAXEL Celgene October 2012
2
Alimta 17 46 PEMETREXED (also Pemetrexed Disodium) Eli Lilly February 2004
3
Avastin 17 46 BEVACIZUMAB Genentech July 2009
4
Cyramza 17 46 RAMUCIRUMAB Eli Lilly April 2014
5
Gemzar 17 46 GEMCITABINE HYDROCHLORIDE Eli Lilly May 1996
6
Gilotrif 17 46 AFATINIB DIMALEATE Boehringer Ingelheim July 2013
7
Hycamtin 17 46 TOPOTECAN HYDROCHLORIDE GlaxoSmithKline/ SmithKline Beecham October 2007/May 1996
8
Iressa 17 46 GEFITINIB AstraZeneca May 2003
9
Keytruda 17 46 PEMBROLIZUMAB Merck September 2014
10
Neutroval 17 tbo-filgrastim Teva Pharmaceutical August 2012
11
Opdivo 17 46 NIVOLUMAB Bristol-Myers Squibb March 2015/ December 2014, March 2015
12
Photodynamic Therapy (& Photofrin) 17 PORFIMER SODIUM Sanofi-aventis January, 1996
13
Photofrin 17 PORFIMER SODIUM QLT January 1998
14
Tarceva 17 46 ERLOTINIB HYDROCHLORIDE Genentech, OSI Pharmaceuticals November, 2004
15
Taxol 17 46 PACLITAXEL Bristol-Myers Squibb August 1997
16
Taxotere 17 46 DOCETAXEL Rhone Poulenc Rorer May 1996
17
Xalkori 17 46 CRIZOTINIB Pfizer August of 2011
18
Xgeva 17 46 DENOSUMAB Amgen June 2013/ November 2010
19
Zometa 17 46 ZOLEDRONIC ACID Novartis August 2001/ February 2002
20
Zykadia 17 46 CERITINIB Novartis April 2014
21
Alecensa 17 ALECTINIB HYDROCHLORIDE Roche December 2015
22
Portazza 17 NECITUMUMAB Eli Lilly November 2015
23
Tagrisso 17 OSIMERTINIB MESYLATE AstraZeneca November 2015

Drugs for Lung Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 945)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Budesonide Approved Phase 4,Phase 2,Phase 3,Phase 1 51333-22-3 63006 5281004
2
Ipratropium Approved Phase 4 22254-24-6, 60205-81-4 43232
3
Terbutaline Approved Phase 4 23031-25-6 5403
4
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 15663-27-1 84093 441203 2767
5
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1 95058-81-4 60750
6
Pemetrexed Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 150399-23-8, 137281-23-3 446556 60843
7
Gefitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 184475-35-2 123631
8
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1 33419-42-0 36462
9
Amiodarone Approved, Investigational Phase 4,Phase 3 1951-25-3 2157
10
Dexmedetomidine Approved, Vet_approved Phase 4 76631-46-4, 113775-47-6 68602 5311068 56032
11
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 1,Early Phase 1 51-43-4 5816
12
Midazolam Approved, Illicit Phase 4,Phase 1 59467-70-8 4192
13 Racepinephrine Approved Phase 4,Phase 2,Phase 1,Early Phase 1
14
Remifentanil Approved Phase 4 132875-61-7 60815
15
Dalteparin Approved Phase 4,Phase 3,Phase 1,Phase 2 9005-49-6
16
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 9005-49-6 772 46507594
17
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 41575-94-4 10339178 498142 38904
18
Zoledronic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 118072-93-8 68740
19
Vinorelbine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 71486-22-1 60780 44424639
20
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 33069-62-4 36314
21
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 216974-75-3
22
Vinblastine Approved Phase 4,Phase 3,Phase 2,Phase 1 865-21-4 13342 241903
23
Everolimus Approved Phase 4,Phase 3,Phase 1,Phase 2 159351-69-6 6442177
24
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 22916-47-8 4189
25
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 53123-88-9 5284616 6436030 46835353
26
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Early Phase 1 137-58-6 3676
27
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 2078-54-8 4943
28
Nedaplatin Approved Phase 4,Phase 3,Phase 2 95734-82-0
29
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 341031-54-7, 557795-19-4 5329102
30
Bupivacaine Approved, Investigational Phase 4,Phase 2,Phase 3 2180-92-9, 38396-39-3 2474
31
Amifostine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 20537-88-6 2141
32
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 50-02-2 5743
33
Nicotine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 54-11-5 942 89594
34
Acetylcysteine Approved, Investigational Phase 4,Phase 2 616-91-1 12035
35
Pancrelipase Approved Phase 4,Phase 3,Phase 2,Phase 1 53608-75-6
36
Irinotecan Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 97682-44-5, 100286-90-6 60838
37
Menthol Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 2216-51-5 16666
38
Trioxsalen Approved Phase 4,Phase 2 3902-71-4 5585
39
Aprepitant Approved, Investigational Phase 4,Phase 3,Phase 2 170729-80-3 151165 6918365
40
Fosaprepitant Approved Phase 4,Phase 3,Phase 2 172673-20-0 219090
41
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 437-38-7 3345
42
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2 57-27-2 5288826
43
Armodafinil Approved, Investigational Phase 4,Phase 1,Phase 2 112111-43-0
44
Modafinil Approved, Investigational Phase 4,Phase 1,Phase 2 68693-11-8 4236
45
Alfentanil Approved, Illicit Phase 4 71195-58-9 51263
46
Bupropion Approved Phase 4,Phase 3,Phase 2,Phase 1 34841-39-9, 34911-55-2 444
47
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
48
Acetaminophen Approved Phase 4,Phase 2,Phase 1 103-90-2 1983
49
Benzocaine Approved Phase 4,Phase 3,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
50
Alginic acid Approved, Experimental Phase 4 9005-32-7

Interventional clinical trials:

(show top 50) (show all 6389)

id Name Status NCT ID Phase Drugs
1 Efficacy of Nebulized Pulmicort Respules in Primary Lung Cancer Patients With COPD Unknown status NCT02504801 Phase 4 Budesonide
2 Positron Emission Tomography (PET)/Computed Tomography (CT) and Roentgen in Lung Cancer: Evaluation of Patients in General Practice Unknown status NCT00675168 Phase 4
3 Chemotherapy Combined With Yangzhengxiaoji Capsule in Patients With Advanced Non-Small Cell Lung Cancer Unknown status NCT02195453 Phase 4 Yangzhengxiaoji Capsule;Placebo Capsule
4 PharmacoEconomic Assessment IRESSA® in the Treatment of Non-Small-Cell Lung Cancer (NSCLC) Unknown status NCT00173524 Phase 4
5 Study of Concurrent Chemo-radiotherapy Combined With Recombinant Human Endostatin for Local Advanced Non-small Cell Lung Cancer (NSCLC) Unknown status NCT01211002 Phase 4 radiotherapy / EP combined with recombinant human endostatin
6 A Study of Endostar Combined With Chemotherapy Followed by Endostar Maintenance Therapy to Treat Advanced Non-small Cell Lung Cancer (NSCLC) Unknown status NCT01028729 Phase 4 Endostar;Gemcitabine-Cisplatin chemotherapy
7 The Randomized Controlled Clinical Trial of Kushen Injection Unknown status NCT02346318 Phase 4 Compound Kushen Injection
8 Maintenance Gemcitabine in the Chinese Advanced Lung Cancer Unknown status NCT01336192 Phase 4 Gemcitabine;Best supportive care
9 Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Advanced NSCLC Unknown status NCT02194556 Phase 4 Sequential and maintenance icotinib;Maintenance icotinib
10 Amiodarone Prophylaxis for Atrial Fibrillation in Patients Undergoing Surgery for Lung Cancer Unknown status NCT00724581 Phase 4 Amiodarone
11 Safety Evaluation of Dexmedetomidine for EBUS-TBNA Unknown status NCT01381627 Phase 4 Remifentanil;Dexmedetomidine
12 Second-line Therapy Study of Combined Chemotherapy and Endostar to Patients With Non-Small Cell Lung Cancer(NSCLC) Unknown status NCT00813332 Phase 4 Endostar(rh recombinant endostatin) plus Docetaxel;Placebo plus Docetaxel
13 Icotinib With Whole Brain Radiation Therapy in NSCLC Patients With Brain Metastases Unknown status NCT01926171 Phase 4 Icotinib plus WBRT
14 First-line Treatment With Icotinib in Elder NSCLC EGFR Mutated Patients Unknown status NCT01646450 Phase 4 Icotinib
15 Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma Unknown status NCT02103257 Phase 4 Sequential Icotinib Plus Chemotherapy;Icotinib
16 Comparison the Level of CTGF Protein and Related Cytokine in Pleural Effusion Unknown status NCT00313066 Phase 4
17 Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors Unknown status NCT00454376 Phase 4
18 Residual Vein Thrombosis and the Optimal Duration of Low Molecular Weight Heparin in Cancer Patients With Deep Vein Thrombosis Unknown status NCT00450645 Phase 4 low molecular weight heparin
19 Safety Study of Adjuvant Docetaxel-Carboplatin Treatment for Resected Lung Cancer Completed NCT00883675 Phase 4 Docetaxel-Carboplatin
20 Coagulation Profile in Patients Undergoing Video Assisted Thorascopic Surgery (VATS) for Lung Cancer Completed NCT01741506 Phase 4 Dalteparin (Fragmin®)
21 Chemotherapy for Patients With Non-Small Cell Lung Cancer Completed NCT00380718 Phase 4 pemetrexed
22 Non-small Cell Lung Cancer Registry Completed NCT00099541 Phase 4 zoledronic acid
23 A Study in Non-squamous Non Small Cell Lung Cancer in Asian Patients Completed NCT01020786 Phase 4 Pemetrexed;Carboplatin
24 Fentanyl Matrix in Lung Cancer Pain Completed NCT01060137 Phase 4 fentanyl matrix
25 A Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung Cancer Completed NCT01196078 Phase 4 erlotinib [Tarceva];vinorelbine
26 A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present EGFR Mutations Completed NCT01287754 Phase 4 erlotinib [Tarceva]
27 Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis Completed NCT00762346 Phase 4 zometa
28 Concurrent Chemoradiotherapy (CCRT) With Paclitaxel Plus Cisplatin in LA Non-small-cell Lung Cancer (NSCLC) Completed NCT00686322 Phase 4 Concurrent chemoradiotherapy (paclitaxel plus cisplatin plus radiotherapy)
29 Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC) Completed NCT00770588 Phase 4 Gefitinib;Placebo
30 A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Following 4 Cycles of Platinum-based Chemotherapy Without Disease Progression Completed NCT01230710 Phase 4 Erlotinib
31 A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer. Completed NCT00451906 Phase 4 Platinum-based chemotherapy;Bevacizumab [Avastin]
32 Recombinant Human Endostatin Combined With NP in Neoadjuvant Chemotherapy of Stage ⅢA NSCLC Completed NCT02497118 Phase 4 Endostatin;Vinorelbine;Cisplatin
33 "Red Morphine Drops" for Symptomatic Treatment of Dyspnoea in Lung Cancer Completed NCT00338481 Phase 4 Morphine p.o.;Morphine s.c.
34 An Expanded Access Program of Tarceva (Erlotinib) in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) Completed NCT00949910 Phase 4 Erlotinib
35 Pemetrexed Followed by Docetaxel or in Reverse Sequence Completed NCT01442909 Phase 4 Docetaxel and pemetrexed
36 A Study of Avastin in Combination With Chemotherapy for Treatment of Colorectal Cancer and Non-Small Cell Lung Cancer (ARIES) Completed NCT00388206 Phase 4
37 RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation Completed NCT01317615 Phase 4 RAD001;Paclitaxel;Carboplatin
38 Carotene and Retinol Efficacy Trial Completed NCT00712647 Phase 4 Beta Carotene and Retinol
39 Screening Non Small Cell Lung Cancer With Bone Metastasis and Efficacy and Safety Research of Receiving Bisphosphonates Completed NCT00765687 Phase 4 bisphosphates
40 A Study of First or Second Line Treatment With Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer Completed NCT01066884 Phase 4 erlotinib [Tarceva]
41 Modafinil for the Treatment of Fatigue in Lung Cancer V9.0 Completed NCT00829322 Phase 4 Modafinil;Placebo
42 Open-label Study in Patients With Metastatic NSLC Treated With Cisplatin, Gemcitabine and Bevacizumab Completed NCT02316327 Phase 4 gemcitabine, cisplatin and bevacizumab
43 Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation Completed NCT02208843 Phase 4 Afatinib
44 Anesthesia in Flexible Bronchoscopy for Lung Cancer Diagnostic Completed NCT00440960 Phase 4 propofol;midazolam;alfentanil;lidocaine
45 Neulasta® in Subjects With Advanced Non-Small-Cell Lung Cancer (NSCLC) During Chemotherapy Completed NCT00115206 Phase 4 Neulasta® (pegfilgrastim)
46 Progression Free Survival (PFS) Using Erlotinib for Non-Small-Cell Lung Cancer (NSCLC) in Chinese Population Completed NCT02000531 Phase 4 Erlotinib;Chemotherapy
47 Bio-behavioral Lung Cancer Prevention Program Completed NCT00322205 Phase 4 zyban
48 A Study on the Long Term Survivals in an Expand Access Program (EAP) of Iressa Completed NCT01000740 Phase 4
49 Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly Completed NCT02151149 Phase 4 nab-paclitaxel;Carboplatin
50 Cryotherapy Combine Icotinib for Advanced NSCLC Treatment Completed NCT02744664 Phase 4 Icotinib

Search NIH Clinical Center for Lung Cancer

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: carcinoma, non-small-cell lung

Genetic Tests for Lung Cancer

Genetic tests related to Lung Cancer:

id Genetic test Affiliating Genes
1 Non-Small Cell Lung Cancer 29
2 Lung Cancer 29 24 GSTM1
3 Lung Cancer, Protection Against 29
4 Neoplasm of Lung 29
5 Neoplasm of the Lung 29
6 Alveolar Cell Carcinoma 29
7 Lung Cancer, Somatic 24 KRAS
8 Adenocarcinoma of Lung, Somatic 24 PRKN

Anatomical Context for Lung Cancer

MalaCards organs/tissues related to Lung Cancer:

39
Lung, Brain, Breast, Testes, Bone, Endothelial, T Cells

Publications for Lung Cancer

Articles related to Lung Cancer:

(show top 50) (show all 13729)
id Title Authors Year
1
Image Findings of Rare Case of Peritoneal Carcinomatosis from Non Small Cell Lung Cancer and Response to Erlotinib in F-18 FDG Positron Emission Tomography/Computed Tomography. ( 28533646 )
2017
2
Prognostic roles of mRNA expression of notch receptors in non-small cell lung cancer. ( 28061457 )
2017
3
Tissue Factor Pathway Inhibitor-1 Is a Valuable Marker for the Prediction of Deep Venous Thrombosis and Tumor Metastasis in Patients with Lung Cancer. ( 28246607 )
2017
4
Determining EGFR-TKI sensitivity of G719X and other uncommon EGFR mutations in non-small cell lung cancer: Perplexity and solution (Review). ( 28184913 )
2017
5
The Biological Effects of Dickkopf1 on Small Cell Lung Cancer Cells and Bone Metastasis. ( 28081731 )
2017
6
Long noncoding RNA LINC01186, regulated by TGF-I^/SMAD3, inhibits migration and invasion through Epithelial-Mesenchymal-Transition in lung cancer. ( 28119085 )
2017
7
ROS1 fusions rarely overlap with other oncogenic drivers in non-small cell lung cancer. ( 28088512 )
2017
8
The Pseudogene DUXAP8 Promotes Non-small-cell Lung Cancer Cell Proliferation and Invasion by Epigenetically Silencing EGR1 and RHOB. ( 28131418 )
2017
9
Ganoderic acid targeting nuclear factor erythroid 2-related factor 2 in lung cancer. ( 28349780 )
2017
10
Endobronchial ultrasound guided transbronchial needle aspiration combining with immunohistochemistry and genotype in lung cancer: A single-center, 55 cases retrospective study. ( 28951780 )
2017
11
Variations within 3'-UTR of MDM4 gene contribute to clinical outcomes of advanced non-small cell lung cancer patients following platinum-based chemotherapy. ( 27462918 )
2017
12
Thyroid transcription factor 1 expression is associated with outcome of patients with non-squamous non-small cell lung cancer treated with pemetrexed-based chemotherapy. ( 28218046 )
2017
13
Integrated analysis profiles of long non-coding RNAs reveal potential biomarkers of drug resistance in lung cancer. ( 28415620 )
2017
14
Identification of curcumin-inhibited extracellular matrix receptors in non-small cell lung cancer A549 cells by RNA sequencing. ( 28618934 )
2017
15
Inhibition of CCR7 promotes NF-I_B-dependent apoptosis and suppresses epithelial-mesenchymal transition in non-small cell lung cancer. ( 28339080 )
2017
16
Association between UGT1A1*28*28 genotype and lung cancer in the Japanese population. ( 27832386 )
2017
17
Preoperative short-term plus postoperative physical therapy versus postoperative physical therapy alone for patients undergoing lung cancer surgery: retrospective analysis of a nationwide inpatient database. ( 28950377 )
2017
18
The Cdc2/Cdk1 inhibitor, purvalanol A, enhances the cytotoxic effects of taxol through Op18/stathmin in non-small cell lung cancer cells inA vitro. ( 28534969 )
2017
19
MicroRNA-30a-5p suppresses epithelial-mesenchymal transition by targeting profilin-2 in high invasive non-small cell lung cancer cell lines. ( 28405690 )
2017
20
Potential Antitumor Activity of SIM-89 in Non-Small Cell Lung Cancer Cells. ( 28332364 )
2017
21
Identification of circulating long non-coding RNAA GAS5 as a potential biomarker for non-small cell lung cancer diagnosisnon-small cell lung cancer, long non-coding RNA, plasma, GAS5, biomarker. ( 28339045 )
2017
22
IgG4-related disease of the lung: a rare differential diagnosis to lung cancer after positive positron emission tomography and biopsy. ( 28950319 )
2017
23
A herpes simplex virus type 2-encoded microRNA promotes tumor cell metastasis by targeting suppressor of cytokine signaling 2 in lung cancer. ( 28468588 )
2017
24
Longitudinal cell-free DNA analysis in patients with small cell lung cancer reveals dynamic insights into treatment efficacy and disease relapse. ( 28951314 )
2017
25
HBXIP suppression reduces cell proliferation and migration and its overexpression predicts poor prognosis in non-small-cell lung cancer. ( 28718367 )
2017
26
Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature. ( 28285683 )
2017
27
Inversin correlates with the malignant phenotype of non-small cell lung cancer and promotes the invasiveness of lung cancer cells. ( 28618971 )
2017
28
The downstream of tyrosine kinase 7 is reduced in lung cancer and is associated with poor survival of patients with lung cancer. ( 28393246 )
2017
29
Dysregulation of CUL4A and CUL4B Ubiquitin Ligases in Lung Cancer. ( 27974468 )
2017
30
Long Intergenic Noncoding RNA 319 (linc00319) Promotes Cell Proliferation and Invasion in Lung Cancer Cells by Directly Downregulating the Tumor Suppressor MiR-32. ( 28800794 )
2017
31
Highly expressed long non-coding RNA FOXD2-AS1 promotes non-small cell lung cancer progression via Wnt/I^-catenin signaling. ( 28132805 )
2017
32
DDX17 nucleocytoplasmic shuttling promotes acquired gefitinib resistance in non-small cell lung cancer cells via activation of I^-catenin. ( 28259822 )
2017
33
Epidermal growth factor receptor-mutant lung cancer in Down syndrome: a case presentation and review of the literature. ( 28903458 )
2017
34
CD73/NT5E is a target of miR-30a-5p and plays an important role in the pathogenesis of non-small cell lung cancer. ( 28158983 )
2017
35
Identification of miRa89124a as a novel diagnostic and prognostic biomarker in nona89small cell lung cancer for chemotherapy. ( 28534972 )
2017
36
SPOP promotes SIRT2 degradation and suppresses non-small cell lung cancer cell growth. ( 28073696 )
2017
37
[Overexpression of liver kinase B1 inhibits the proliferation of lung cancer cells]. ( 28031112 )
2017
38
XPG genetic polymorphisms and clinical outcome of patients with advanced non-small cell lung cancer under platinum-based treatment: a meta-analysis of 12 studies. ( 28314991 )
2017
39
IL-17A and IL-17F single nucleotide polymorphisms associated with lung cancer in Chinese population. ( 26073462 )
2017
40
Insulin-like growth factor binding protein-4 inhibits cell growth, migration and invasion, and downregulates COX-2 expression in A549 lung cancer cells. ( 28150906 )
2017
41
UGT1A1 polymorphisms with irinotecan-induced toxicities and treatment outcome in Asians with Lung Cancer: a meta-analysis. ( 28502040 )
2017
42
Successful Treatment with Gefitinib in Advanced Non-Small Cell Lung Cancer after Acquired Resistance to Osimertinib. ( 28532569 )
2017
43
PM2.5 exposure-induced autophagy is mediated by lncRNA loc146880 which also promotes the migration and invasion of lung cancer cells. ( 27836757 )
2017
44
Emerging roles of RAC1 in treating lung cancer patients. ( 27790713 )
2017
45
Intracellular calcium promotes radioresistance of non-small cell lung cancer A549 cells through activating Akt signaling. ( 28351325 )
2017
46
Study on expression of CDH4 in lung cancer. ( 28095912 )
2017
47
Endovascular stenting for end-stage lung cancer patients with superior vena cava syndrome post first-line treatments - A single-center experience and literature review. ( 28501315 )
2017
48
Stability of the cancer target DDIAS is regulated by the CHIP/HSP70 pathway in lung cancer cells. ( 28079882 )
2017
49
Desmoglein-2 is overexpressed in non-small cell lung cancer tissues and its knockdown suppresses NSCLC growth by regulation of p27 and CDK2. ( 27629878 )
2017
50
Epigenetic regulation of epithelial-mesenchymal transition by KDM6A histone demethylase in lung cancer cells. ( 28698146 )
2017